pepscience

Bioregulator research · RESEARCH PROFILE

Pinealon

A tripeptide investigated in neuronal stress and gene-regulation models.

1 specification·19 source documents·Source updated Jul 13, 2026

At a glance

A tripeptide investigated in neuronal stress and gene-regulation models.

This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.

How it works

Pinealon is associated with the Glu-Asp-Arg sequence. Research discussions focus on cellular stress responses and regulation of neuronal function.[4][3][8]

Potential benefits & side effects

Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.

Potential benefits & research findings

The cited work explores experimental neuroprotection and related outcomes. Short research courses described in days should retain that duration rather than being expanded into an eight-week schedule.[3][9][6]

Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.

Side effects & evidence limitations

Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Pinealon.

Source-reported adverse effects and cautions

  • Generally well tolerated; occasional mild injection‑site reactions (redness, itching) may occur with subcutaneous administration[15].
  • Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.

    Editorial responsibility
    Pep Science editorial desk
    Last independent review
    Not yet recorded
    Editorial standards & corrections

    SPECIFICATIONS & SOURCE SCHEDULES

    Explore a vial size

    Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.

    Showing 20 mg · 1 source tables

    Source-derived research information. Table phases retain the source’s actual duration; open-ended phases are not converted into a fixed eight-week course. Review the original study before interpreting a schedule.

    Standard Approach (3 mL = ~6.67 mg/mL)

    1–5 Days6–14 Days
    DaysDaily DoseUnits (per injection) (mL)
    Days 1–51.0 mg (1,000 mcg)15 units (0.15 mL)
    Days 6–141.5 mg (1,500 mcg)22.5 units (0.225 mL)
    Days 15–202.0 mg (2,000 mcg)30 units (0.30 mL)

    Frequency: Inject once daily subcutaneously, preferably in the morning or early afternoon. Standard cycles are 10–20 days, with the option to extend to 28 days if desired[5][6]. Repeat cycles can be administered every 2–3 months as needed.

    Additional schedule context & duration

    Concise summary of the once‑daily regimen.

    • Goal: Support neuroprotection, cognitive function, and cellular resilience in brain tissue through peptide bioregulation[3][7].
    • Schedule: Daily subcutaneous injections for 10–20 days (extendable to 28 days).
    • Dose Range: 1.0–2.0 mg daily with gradual titration.
    • Reconstitution: 3.0 mL per 20 mg vial (~6.67 mg/mL) for accurate unit measurements.
    • Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

    Suggested daily titration approach.

    • Start: 1.0 mg daily for Days 1–5 to assess tolerance.
    • Increase: 1.5 mg daily for Days 6–14.
    • Target: 2.0 mg daily for Days 15–20 (or up to Day 28 if extending cycle).
    • Frequency: Once per day (subcutaneous), preferably morning or early afternoon.
    • Cycle Length: Standard 10–20 days; repeat cycles every 2–3 months.
    • Timing: Consistent daily timing; rotate injection sites.

    Read this source protocol ↗ · View cited documents ↓

    Preparation

    Preparation and stability depend on the formulation, diluent, container and handling. The source-specific notes below apply to the selected record.
    Reconstitution Steps
    1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
    2. Inject slowly down the vial wall; avoid foaming.
    3. Gently swirl/roll until dissolved (do not shake).
    4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

    Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.

    Storage Instructions

    Proper storage preserves peptide quality.

    • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
    • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); prepare aliquots if needed and avoid freeze–thaw.
    • Allow vials to reach room temperature before opening to reduce condensation uptake.

    Injection Technique

    General subcutaneous guidance from clinical best‑practice resources[16].

    • Clean the vial stopper and skin with alcohol; allow to dry.
    • Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[17][18].
    • Do not aspirate for subcutaneous injections; inject slowly and steadily[17].
    • Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[19].

    Materials & quantity planning

    Source materials checklist · 20 mg

    Plan based on standard 10–20 day cycles with once‑daily administration.

    • Peptide Vials (Pinealon, 20 mg each):

      • 10‑day cycle ≈ 1 vial
      • 20‑day cycle ≈ 2 vials
      • 28‑day cycle ≈ 3 vials
    • Insulin Syringes (U‑100):

      • Per day: 1 syringe
      • 10‑day cycle: 10 syringes
      • 20‑day cycle: 20 syringes
      • 28‑day cycle: 28 syringes
    • Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.

      • 10‑day cycle (1 vial): 3 mL1 × 10 mL bottle
      • 20‑day cycle (2 vials): 6 mL1 × 10 mL bottle
      • 28‑day cycle (3 vials): 9 mL1 × 10 mL bottle
    • Alcohol Swabs: One for the vial stopper + one for the injection site each day.

      • Per day: 2 swabs
      • 10‑day cycle: 20 swabs
      • 20‑day cycle: 40 swabs
      • 28‑day cycle: 56 swabs → recommend 1 × 100‑count box


    Calculate a phased quantity

    Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.

    Complete each phase to calculate totals.

    Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.

    FOLLOW THE EVIDENCE

    References & further reading

    Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.

    Continue exploring

    Related topics are not interchangeable compounds or formulations.